Numares to Develop Multi-biomarker Test of SPMS Transition

Numares to Develop Multi-biomarker Test of SPMS Transition

311069

Numares to Develop Multi-biomarker Test of SPMS Transition

Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting MS (RRMS) to secondary progressive MS (SPMS), enabling patients to receive timely treatment and improve their outcomes. The agreement follows a collaboration established between both parties in 2017, under…

You must be logged in to read/download the full post.